ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

ClinicalTrials.gov ID: NCT07525375

Public ClinicalTrials.gov record NCT07525375. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 1:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) Versus Placebo in Participants of 4 to Less Than 12 Years of Age With Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF)

Study identification

NCT ID
NCT07525375
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
69 participants

Conditions and interventions

Conditions

Interventions

  • BFF MDI Combination Product
  • GP MDI Combination Product
  • Placebo MDI Combination Product

Combination Product

Eligibility (public fields only)

Age range
4 Years to 11 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 13, 2026
Primary completion
May 22, 2029
Completion
May 22, 2029
Last update posted
Apr 21, 2026

2026 – 2029

United States locations

U.S. sites
11
U.S. states
8
U.S. cities
11
Facility City State ZIP Site status
Research Site Bakersfield California 93301 Not yet recruiting
Research Site Long Beach California 90806 Not yet recruiting
Research Site San Diego California 92123 Not yet recruiting
Research Site Miami Florida 33125 Not yet recruiting
Research Site Pembroke Pines Florida 33026 Not yet recruiting
Research Site Owensboro Kentucky 42301 Recruiting
Research Site Lafayette Louisiana 70508 Not yet recruiting
Research Site Boston Massachusetts 02114 Not yet recruiting
Research Site Columbia Missouri 65203 Not yet recruiting
Research Site Cincinnati Ohio 45229 Not yet recruiting
Research Site Oklahoma City Oklahoma 73120 Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07525375, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 21, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07525375 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →